Publications by authors named "Frank DiGiorgio"
Alcohol use disorder (AUD) affects >15 million people in the United States. Current pharmacotherapeutic treatments for AUD are only modestly effective, necessitating the identification of new targets for medications development. The cannabinoid receptor type 1 (CB1) has been a target of interest for the development of medications for substance use disorders and other compulsive disorders.
View Article and Find Full Text PDFArticle Synopsis
- - IBNtxA is a new μ-opioid receptor agonist derived from naltrexone, showing promise for pain relief (anti-nociception) without significant side effects or addiction potential.
- - In studies, a 3 mg/kg dose of IBNtxA was found to be as effective as 10 mg/kg of morphine in pain relief tests, while also reducing morphine's side effects such as hyperactivity and withdrawal symptoms.
- - IBNtxA exhibited complex interactions with various opioid receptors, suggesting it has a unique mechanism of action that could make it a valuable candidate for future pain management medications.